Bluejay Diagnostics, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Bluejay Diagnostics, Inc. (BJDX) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $4.79 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2024-11-07
- Bluejay Diagnostics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-09-30 was $4.79K.
- Bluejay Diagnostics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-06-30 was $6.01K, a 78.30% decline year-over-year.
- Bluejay Diagnostics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-03-31 was $11.87K, a 78.30% decline year-over-year.
- Bluejay Diagnostics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2023-09-30 was -$42.48K.
- Bluejay Diagnostics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $24.39K, a 94.37% decline from fiscal 2022.
- Bluejay Diagnostics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $433.00K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2024-09-30 | $4.79K 10-Q · filed 2024-11-07 | $10.80K derived: sum of 2 quarters · filed 2024-11-07 | $22.68K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2024-06-30 | $6.01K 10-Q · filed 2024-11-07 | $17.88K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2024-03-31 | $11.87K 10-Q · filed 2024-11-07 | |||
| 2023-12-31 | $24.39K 10-K · filed 2024-03-28 | |||
| 2023-09-30 | -$42.48K 10-Q · filed 2024-11-07 | -$14.78K derived: sum of 2 quarters · filed 2024-11-07 | $39.95K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $27.70K 10-Q · filed 2024-11-07 | $82.43K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $54.73K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $433.00K 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |